Brokers Offer Predictions for Apellis Pharmaceuticals, Inc.’s FY2026 Earnings (NASDAQ:APLS)

Posted by Defense World Staff on Aug 9th, 2023

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) – Research analysts at Wedbush lowered their FY2026 earnings per share (EPS) estimates for Apellis Pharmaceuticals in a note issued to investors on Monday, August 7th. Wedbush analyst L. Chico now expects that the company will post earnings per share of $2.19 for the year, down from their prior forecast of $2.41. Wedbush currently has a “Neutral” rating and a $29.00 target price on the stock. The consensus estimate for Apellis Pharmaceuticals’ current full-year earnings is ($5.03) per share. Wedbush also issued estimates for Apellis Pharmaceuticals’ FY2027 earnings at $3.12 EPS.

Apellis Pharmaceuticals (NASDAQ:APLS – Get Free Report) last issued its quarterly earnings data on Monday, July 31st. The company reported ($1.02) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.35) by $0.33. Apellis Pharmaceuticals had a negative return on equity of 212.82% and a negative net margin of 356.02%. The company had revenue of $95.00 million during the quarter, compared to the consensus estimate of $70.38 million. During the same period last year, the company earned ($1.46) earnings per share. The firm’s revenue was up 482.8% compared to the same quarter last year.

Other equities research analysts have also recently issued research reports about the company. Needham & Company LLC decreased their target price on Apellis Pharmaceuticals from $110.00 to $60.00 and set a “buy” rating for the company in a research note on Monday, July 31st. The Goldman Sachs Group raised their target price on Apellis Pharmaceuticals from $124.00 to $141.00 and gave the stock a “buy” rating in a research note on Friday, April 14th. JPMorgan Chase & Co. cut Apellis Pharmaceuticals from an “overweight” rating to a “neutral” rating and decreased their target price for the stock from $72.00 to $60.00 in a research note on Thursday, August 3rd. Oppenheimer decreased their target price on Apellis Pharmaceuticals from $108.00 to $88.00 in a research note on Monday, July 31st. Finally, HC Wainwright reaffirmed a “buy” rating and set a $82.00 target price on shares of Apellis Pharmaceuticals in a research note on Monday. Six investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $67.86.

View Our Latest Report on Apellis Pharmaceuticals

Apellis Pharmaceuticals Price Performance

Shares of APLS opened at $24.11 on Tuesday. Apellis Pharmaceuticals has a 1 year low of $19.83 and a 1 year high of $94.75. The company has a debt-to-equity ratio of 0.27, a current ratio of 5.11 and a quick ratio of 4.52. The company has a market capitalization of $2.84 billion, a price-to-earnings ratio of -4.14 and a beta of 1.17. The business has a 50-day moving average of $68.97 and a 200-day moving average of $70.30.

Insider Activity at Apellis Pharmaceuticals

In related news, CFO Timothy Eugene Sullivan sold 69,779 shares of the stock in a transaction on Monday, June 5th. The stock was sold at an average price of $88.80, for a total value of $6,196,375.20. Following the completion of the sale, the chief financial officer now directly owns 77,713 shares of the company’s stock, valued at approximately $6,900,914.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In related news, CFO Timothy Eugene Sullivan sold 69,779 shares of the stock in a transaction on Monday, June 5th. The stock was sold at an average price of $88.80, for a total value of $6,196,375.20. Following the completion of the sale, the chief financial officer now directly owns 77,713 shares of the company’s stock, valued at approximately $6,900,914.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Pascal Deschatelets sold 12,000 shares of the stock in a transaction on Thursday, June 8th. The shares were sold at an average price of $91.35, for a total value of $1,096,200.00. Following the completion of the sale, the insider now directly owns 1,040,313 shares of the company’s stock, valued at $95,032,592.55. The disclosure for this sale can be found here. In the last three months, insiders sold 147,818 shares of company stock valued at $12,984,937. 7.50% of the stock is owned by insiders.

Institutional Investors Weigh In On Apellis Pharmaceuticals

A number of hedge funds have recently made changes to their positions in APLS. Bank of New York Mellon Corp raised its stake in shares of Apellis Pharmaceuticals by 5.8% during the 1st quarter. Bank of New York Mellon Corp now owns 315,480 shares of the company’s stock worth $16,029,000 after purchasing an additional 17,287 shares during the period. American Century Companies Inc. bought a new stake in shares of Apellis Pharmaceuticals during the 1st quarter worth $820,000. US Bancorp DE raised its stake in shares of Apellis Pharmaceuticals by 391.2% during the 1st quarter. US Bancorp DE now owns 1,110 shares of the company’s stock worth $56,000 after purchasing an additional 884 shares during the period. MetLife Investment Management LLC raised its stake in shares of Apellis Pharmaceuticals by 67.0% during the 1st quarter. MetLife Investment Management LLC now owns 41,293 shares of the company’s stock worth $2,098,000 after purchasing an additional 16,567 shares during the period. Finally, Rhumbline Advisers raised its stake in shares of Apellis Pharmaceuticals by 5.2% during the 1st quarter. Rhumbline Advisers now owns 77,764 shares of the company’s stock worth $3,951,000 after purchasing an additional 3,835 shares during the period. 93.72% of the stock is currently owned by institutional investors.

About Apellis Pharmaceuticals

(Get Free Report)

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, cold agglutinin disease, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, amyotrophic lateral sclerosis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy (GA).